Treatment with interferon in hepatitis C
Cernadas C, Pichon Riviere A
Record ID 32005000649
The aim of this report is to investigate treatment with interferon in hepatitis C
Authors' results and conclusions: In nine clinical trials comparing the effectiveness of pegylated interferon vs standard treatment (alpha interferon + rivabirin), it was observed that pegylated interferon has more capacity to obtain a sustained viral response (defined as the absence of viral RNA, 6 months after the treatment is completed). In general, Pegylated interferon can increase between 10% and 20% the number of patients with sustained viral response (approximately 70%-80% of success vs 50%-60% with the standard treatment). This new Interferon is also administered together with ribavirin. It is important to bear in mind that the results from the reports published refer, in general, to intermediate end-points (such as viral load, transaminase normalization, etc.), though important, it has not been clearly studied how these intermediate results impact on significant clinical findings such as decrease in mortality, hepatocellular carcinoma or cirrhosis.
Authors' recomendations: It is estimated that in Argentina, the prevalence of Hepatitis C is 0.6% in the general population. By extrapolating data from the NICE and the Consensus on Hepatitis C of the Argentine Association for the Study of Liver Diseases (Consenso de Hepatitis C de la Asociacion Argentina para el Estudio de las Enfermedades del Hegado), it is possible to estimate that out of 100,000 people, approximately 22 would be indicated treatment with interferon.
Authors' methods: Overview
Project Status: Completed
URL for project: http://www.iecs.org.ar/
Year Published: 2003
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Hepatitis C, Chronic
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.